Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas

Abstract

CUEDC2, a newly reported protein, plays critical roles in many biological processes, such as cell cycle, inflammation and tumorigenesis, however, its expression in ovarian serious carcinoma is still poorly understood. In this study, we performed an immunohistochemical study on 101 cases of ovarian serous carcinoma tissues to investigate whether CUEDC2 is a useful biomarker to evaluate the progression of ovarian serous carcinomas. The data showed that the overexpression of CUEDC2 was observed in 59.4% of ovarian serous carcinoma tissue samples and correlated with histopathological grade, patient age at diagnosis, FIGO stage and recurrence. To assess the clinical relevance of CUEDC2, we analyzed the survival follow-up information, the results showed that CUEDC2-positive expression was associated with a shorter disease-free survival time, the median disease-free survival time of CUEDC2-positive patients was 36.0 months compared with 53.9 months of CUEDC2-negative ones (Log-rank χ2=6.149, P=0.013). Collectively, our results suggested that CUEDC2 may be a promising biomarker to evaluate the progression of serous ovarian carcinoma and to predict likely relapse of ovarian serous carcinoma.

BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma

“…In our study, A-catenin staining was predominantly found in the cytoplasm or in the cytoplasm and membrane in both LGSOC and HGSOC. Lee et al 16 reported that nuclear expression of A-catenin was associated with high-grade tumors and worse median survival; no association was found between membrane or cytoplasmic staining and histological 14 reported that A-catenin expression was not different between LGSOC and HGSOC. However, they concluded that overexpression was associated with advanced stages and poor OS.…”

“…In our study, A-catenin expression was not associated with stage, histological grade, platinum chemotherapy, or OS in LGSOCs or HGSOCs. 14 The strength of this study is that it is the first investigation that correlated the IHC expression of BRCA1, Ki67, and A-catenin in response to platinum-based chemotherapy and prognosis in a selected sample of Brazilian woman with serous OCs. The main limitations of this study are its retrospective nature and immunohistochemical technique based on TMA.…”

“…With respect to the statistical analysis, A-catenin expression was classified into 2 categories based on the combination of membranous, cytoplasmic, and nuclear staining. 14 Cases in the first category, which included cytoplasmic and/or nuclear with or without membranous staining independent of intensity, were classified as positive. Cases in the second category, which included only membranous staining independent of intensity or no staining, were considered negative (Fig.…”

A Study of β-Catenin and PTEN Expression in Ovarian Surface Epithelial Neoplasms and their Correlation with Grade and Stage in Malignant Cases

“…So, recently more attention has been focused on the molecular markers of the P13K/AKT pathway and WNT /β-catenin pathway, which are being widely studied in ovarian carcinoma. 18,19 In this scenario, an institutional based cross-sectional observational study was done among the different types of ovarian carcinoma cases with a purpose to assess the β-catenin and PTEN expression and study their correlation with histological grade and stage of ovarian carcinoma by immunohistochemistry.…”

Clinical implication of Tiam1 overexpression in the prognosis of patients with serous ovarian carcinoma

“…The H&E-stained slides of the different biopsies were reviewed by two experienced pathologists and one appropriate paraffin block was selected for this study. Histopathological grading was performed using the World Health Organization (Pathology and Genetics Tumors of Gynecological System) criteria (with 72 low-grade tumors and 110 high-grade tumors) (19 (19). None of the ovarian carcinoma patients received pre-operative radiation or chemotherapy prior to surgery.…”